Testing effectiveness (Phase 2)Study completedNCT02230176
What this trial is testing
Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II
Who this might be right for
Pancreatic Neuroendocrine Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris 84